Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
about
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysisTreatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settingsOutcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazoleCryptococcus and Phagocytes: Complex Interactions that Influence Disease OutcomeExtensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and StrategiesPreventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral TherapyFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsIntegrated therapy for HIV and cryptococcosisHIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited SettingsCryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness AnalysisRapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TORClinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditionsIn vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformansPredictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune statusTreatment of cryptococcosis in the setting of HIV coinfection.Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosisA prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA:protein N-myristoyltransferase (Nmt) is Nmt-dependent.Disseminated Cryptococcosis with Adrenal Insufficiency and Meningitis in an Immunocompetent IndividualRisk factors for mortality from primary cryptococcosis in patients with HIV.Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D studyManagement of cryptococcosis: how are we doing?Major role for amphotericin B-flucytosine combination in severe cryptococcosis.Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.SREB, a GATA transcription factor that directs disparate fates in Blastomyces dermatitidis including morphogenesis and siderophore biosynthesis.Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in MalawiCryptococcal meningitis: epidemiology and therapeutic options.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerClinical pharmacokinetics of oral controlled-release 5-fluorocytosineVariation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994.Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents.The past, present and future of antimycotic combination therapy.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.HTLV-1 and HIV infections of the central nervous system in tropical areasSymptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxisIn vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and AfricaEffects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages
P2860
Q21144604-8DB9B0E0-9C86-4765-9040-911C0E87191AQ24241096-9B915FF1-4D3C-497C-8E2D-1F92E406B0A1Q24678763-ACB83E2A-90B1-4CF8-8100-75EBEB73776BQ26767978-D59DD927-291C-40B4-B088-36CA84C96F4FQ26852378-C8025051-D77D-40A3-A1C0-B12CFE4D73B7Q26994750-08AD9217-FBE7-4B86-8EB9-3FA10E06F419Q27012487-BB082F4C-B86B-43C2-9C26-30A49019FEFBQ27025299-8E1CBFEF-CA43-4DC1-890D-7B6E97191988Q28077707-1367EBEE-2CCD-4EC7-8ED0-F266AF05BB49Q28078958-9A1F8CB6-E3E7-4346-9A58-5440AA4C0D30Q28274334-D63B7054-98A9-4099-A38D-3244902128DCQ28361576-D8D26530-1907-479E-8211-0E7E84CB8446Q28365296-DB256B44-7009-49D1-A489-DDCD17466C49Q28369024-E9174678-7293-45DE-AF61-F502E16C4497Q28488912-B9FD7F02-6935-46BE-9A3D-2EBD22BFA17EQ30366117-157724B5-5C8C-4CF7-9B91-A18B8D0550FAQ30433949-A18F499D-40F0-4D69-AF97-2A974DFAF393Q30495712-75192034-100F-48F6-9FCB-D549C4DDEE9BQ32064880-AD42585B-8ADE-4105-A5EF-34E4AEF57417Q32181959-4752D0B9-11D8-4939-80FD-DCC715DC427AQ33157255-147C5FFA-2A63-497D-A021-2F3B2791CC1EQ33272469-784F5573-2AB9-4AC8-B74E-9A566ABC9086Q33272471-8A3259E5-E8FD-49F0-A417-6A79016CE661Q33358131-40E291D9-0B5F-4A71-ABB8-E5B8DB57E888Q33523050-B7D96896-A166-4679-9E75-AFB0682C16D5Q33532335-72F3CF40-A640-46AD-AF68-B9D9BC33AD46Q33549666-F5DC20E0-5F6A-46FF-A1B2-1D75711FA02EQ33588561-667CFB94-031B-48C3-8233-A39B793B811CQ33633343-E9A2DC44-DB89-4BA4-BD86-8714D63411C0Q33650105-737A3D29-5A3D-48DA-931B-E6C09E0EA0B3Q33676182-C939CCB1-99C4-47B9-B614-D5CB4367F348Q33686260-558077DA-25F6-454E-AAA8-064342A14155Q33693370-019C19BE-8D1A-4671-AD20-EE31F7FB4566Q33726292-2CF72F9D-A9CD-4E44-9F3C-138CA6ABDD8EQ33760507-7FEE05F1-9BAC-478D-9AE3-43F3FDA60B27Q33857658-9600F455-CD16-4CF4-8016-E396A1B4904CQ33892464-D052A650-8283-427A-96B2-AB9D9BD06AA3Q33892987-A82E18E3-C6CF-41AE-8A62-57037370724FQ33975945-47F0ED55-F5E3-40DD-9145-2401DEEE740BQ33978757-DC4F57ED-7104-432C-A650-2FA5DAD5F2A4
P2860
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@en
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@nl
type
label
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@en
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@nl
prefLabel
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@en
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@nl
P2093
P1476
Treatment of cryptococcal meni ...... nd AIDS Clinical Trials Group.
@en
P2093
Dismukes WE
Graybill JR
Johnson PC
Kerkering T
Moskovitz BL
Powderly WG
P356
10.1056/NEJM199707033370103
P407
P577
1997-07-01T00:00:00Z